AU2002243382A1 - Method of inhibiting infection by HCV, other flaviviridae viruses, and any other virus that complexes to low density lipoprotein or to very low density lipoprotein in blood preventing viral entry into a cell - Google Patents

Method of inhibiting infection by HCV, other flaviviridae viruses, and any other virus that complexes to low density lipoprotein or to very low density lipoprotein in blood preventing viral entry into a cell

Info

Publication number: AU2002243382A1
Authority: AU; Australia
Prior art keywords: seq; amino acids; hcv; ldl; infection
Prior art date: 2000-10-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2002243382A

Other languages

English (en)

Inventor

Vincent Agnello

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-25

Filing date

2001-10-24

Publication date

2002-06-24

2001-10-24 Application filed by Individual filed Critical Individual

2002-06-24 Publication of AU2002243382A1 publication Critical patent/AU2002243382A1/en

Status Abandoned legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims description 50
208000015181 infectious disease Diseases 0.000 title claims description 49
108010007622 LDL Lipoproteins Proteins 0.000 title claims description 41
102000007330 LDL Lipoproteins Human genes 0.000 title claims description 41
241000700605 Viruses Species 0.000 title claims description 37
230000002401 inhibitory effect Effects 0.000 title claims description 17
241000710781 Flaviviridae Species 0.000 title claims description 9
108010062497 VLDL Lipoproteins Proteins 0.000 title description 34
210000004369 blood Anatomy 0.000 title description 8
239000008280 blood Substances 0.000 title description 8
230000007502 viral entry Effects 0.000 title description 2
108010001831 LDL receptors Proteins 0.000 claims description 117
102000000853 LDL receptors Human genes 0.000 claims description 117
102000005962 receptors Human genes 0.000 claims description 48
108020003175 receptors Proteins 0.000 claims description 48
102000004895 Lipoproteins Human genes 0.000 claims description 39
108090001030 Lipoproteins Proteins 0.000 claims description 39
150000001413 amino acids Chemical class 0.000 claims description 39
108090000765 processed proteins & peptides Proteins 0.000 claims description 27
230000027455 binding Effects 0.000 claims description 22
230000000694 effects Effects 0.000 claims description 20
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 18
230000005764 inhibitory process Effects 0.000 claims description 17
241000711975 Vesicular stomatitis virus Species 0.000 claims description 11
108020001756 ligand binding domains Proteins 0.000 claims description 10
230000000903 blocking effect Effects 0.000 claims description 9
230000015572 biosynthetic process Effects 0.000 claims description 6
102000013918 Apolipoproteins E Human genes 0.000 claims description 5
108010025628 Apolipoproteins E Proteins 0.000 claims description 5
102000011965 Lipoprotein Receptors Human genes 0.000 claims description 4
108010061306 Lipoprotein Receptors Proteins 0.000 claims description 4
230000004060 metabolic process Effects 0.000 claims description 4
102000018616 Apolipoproteins B Human genes 0.000 claims description 3
108010027006 Apolipoproteins B Proteins 0.000 claims description 3
230000002222 downregulating effect Effects 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims 8
102000004882 Lipase Human genes 0.000 claims 2
108090001060 Lipase Proteins 0.000 claims 2
239000004367 Lipase Substances 0.000 claims 2
239000003446 ligand Substances 0.000 claims 2
235000019421 lipase Nutrition 0.000 claims 2
241000124008 Mammalia Species 0.000 claims 1
108010033276 Peptide Fragments Proteins 0.000 claims 1
102000007079 Peptide Fragments Human genes 0.000 claims 1
239000002981 blocking agent Substances 0.000 claims 1
239000003085 diluting agent Substances 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
230000009931 harmful effect Effects 0.000 claims 1
230000001939 inductive effect Effects 0.000 claims 1
241000711549 Hepacivirus C Species 0.000 description 202
210000004027 cell Anatomy 0.000 description 141
230000012202 endocytosis Effects 0.000 description 89
241000699666 Mus <mouse, genus> Species 0.000 description 40
238000007901 in situ hybridization Methods 0.000 description 35
210000004185 liver Anatomy 0.000 description 26
241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 24
PPBOKXIGFIBOGK-BDTUAEFFSA-N bvdv Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)C(C)C)[C@@H](C)CC)C1=CN=CN1 PPBOKXIGFIBOGK-BDTUAEFFSA-N 0.000 description 21
238000011081 inoculation Methods 0.000 description 19
210000002966 serum Anatomy 0.000 description 18
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 17
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 16
229960005370 atorvastatin Drugs 0.000 description 16
238000010186 staining Methods 0.000 description 13
108010010234 HDL Lipoproteins Proteins 0.000 description 12
102000015779 HDL Lipoproteins Human genes 0.000 description 12
210000003494 hepatocyte Anatomy 0.000 description 12
241000531123 GB virus C Species 0.000 description 11
230000003827 upregulation Effects 0.000 description 11
102100027221 CD81 antigen Human genes 0.000 description 10
238000010790 dilution Methods 0.000 description 10
239000012895 dilution Substances 0.000 description 10
239000012634 fragment Substances 0.000 description 10
230000007246 mechanism Effects 0.000 description 10
210000003719 b-lymphocyte Anatomy 0.000 description 9
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
239000003814 drug Substances 0.000 description 9
238000011534 incubation Methods 0.000 description 9
230000018352 negative regulation of endocytosis Effects 0.000 description 9
239000002953 phosphate buffered saline Substances 0.000 description 9
238000011830 transgenic mouse model Methods 0.000 description 9
101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 8
238000003556 assay Methods 0.000 description 8
230000002950 deficient Effects 0.000 description 8
229940079593 drug Drugs 0.000 description 8
238000001727 in vivo Methods 0.000 description 8
230000001404 mediated effect Effects 0.000 description 8
241000699670 Mus sp. Species 0.000 description 7
238000010240 RT-PCR analysis Methods 0.000 description 7
241000700584 Simplexvirus Species 0.000 description 7
238000002135 phase contrast microscopy Methods 0.000 description 7
101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 description 6
241000282577 Pan troglodytes Species 0.000 description 6
OILAIQUEIWYQPH-UHFFFAOYSA-N cyclohexane-1,2-dione Chemical compound O=C1CCCCC1=O OILAIQUEIWYQPH-UHFFFAOYSA-N 0.000 description 6
210000002950 fibroblast Anatomy 0.000 description 6
238000010166 immunofluorescence Methods 0.000 description 6
BQVCCPGCDUSGOE-UHFFFAOYSA-N phenylarsine oxide Chemical compound O=[As]C1=CC=CC=C1 BQVCCPGCDUSGOE-UHFFFAOYSA-N 0.000 description 6
241000699660 Mus musculus Species 0.000 description 5
238000007792 addition Methods 0.000 description 5
201000003278 cryoglobulinemia Diseases 0.000 description 5
230000007423 decrease Effects 0.000 description 5
206010073071 hepatocellular carcinoma Diseases 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
238000012317 liver biopsy Methods 0.000 description 5
230000002093 peripheral effect Effects 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
241000283690 Bos taurus Species 0.000 description 4
206010057248 Cell death Diseases 0.000 description 4
108010091326 Cryoglobulins Proteins 0.000 description 4
108060003951 Immunoglobulin Proteins 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
230000009089 cytolysis Effects 0.000 description 4
230000000120 cytopathologic effect Effects 0.000 description 4
230000003828 downregulation Effects 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
230000014509 gene expression Effects 0.000 description 4
102000018358 immunoglobulin Human genes 0.000 description 4
229940072221 immunoglobulins Drugs 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
230000004807 localization Effects 0.000 description 4
239000002609 medium Substances 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
230000010076 replication Effects 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
210000002845 virion Anatomy 0.000 description 4
101150037123 APOE gene Proteins 0.000 description 3
208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 3
101100216294 Danio rerio apoeb gene Proteins 0.000 description 3
241000282412 Homo Species 0.000 description 3
102000006992 Interferon-alpha Human genes 0.000 description 3
108010047761 Interferon-alpha Proteins 0.000 description 3
241000725643 Respiratory syncytial virus Species 0.000 description 3
239000000427 antigen Substances 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
239000000872 buffer Substances 0.000 description 3
244000309466 calf Species 0.000 description 3
210000004748 cultured cell Anatomy 0.000 description 3
238000012303 cytoplasmic staining Methods 0.000 description 3
230000006378 damage Effects 0.000 description 3
238000001514 detection method Methods 0.000 description 3
229950007919 egtazic acid Drugs 0.000 description 3
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
238000010212 intracellular staining Methods 0.000 description 3
230000003902 lesion Effects 0.000 description 3
238000011533 pre-incubation Methods 0.000 description 3
230000010837 receptor-mediated endocytosis Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
241000701161 unidentified adenovirus Species 0.000 description 3
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
108010071619 Apolipoproteins Proteins 0.000 description 2
102000007592 Apolipoproteins Human genes 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
229920002971 Heparan sulfate Polymers 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
241000219061 Rheum Species 0.000 description 2
241000714474 Rous sarcoma virus Species 0.000 description 2
108010077690 Tetraspanin 28 Proteins 0.000 description 2
102100026144 Transferrin receptor protein 1 Human genes 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
239000012888 bovine serum Substances 0.000 description 2
239000013553 cell monolayer Substances 0.000 description 2
238000004440 column chromatography Methods 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000002298 density-gradient ultracentrifugation Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000010494 dissociation reaction Methods 0.000 description 2
230000005593 dissociations Effects 0.000 description 2
238000000684 flow cytometry Methods 0.000 description 2
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
238000012757 fluorescence staining Methods 0.000 description 2
239000007850 fluorescent dye Substances 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
239000002054 inoculum Substances 0.000 description 2
210000002510 keratinocyte Anatomy 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
229940126619 mouse monoclonal antibody Drugs 0.000 description 2
239000013642 negative control Substances 0.000 description 2
230000037311 normal skin Effects 0.000 description 2
IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
239000002356 single layer Substances 0.000 description 2
241000894007 species Species 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
230000008093 supporting effect Effects 0.000 description 2
239000012581 transferrin Substances 0.000 description 2
230000003156 vasculitic effect Effects 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
208000031295 Animal disease Diseases 0.000 description 1
208000035049 Blood-Borne Infections Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
241000283707 Capra Species 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
206010011686 Cutaneous vasculitis Diseases 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 1
102000000589 Interleukin-1 Human genes 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
102000019223 Interleukin-1 receptor Human genes 0.000 description 1
108050006617 Interleukin-1 receptor Proteins 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
238000008214 LDL Cholesterol Methods 0.000 description 1
238000003231 Lowry assay Methods 0.000 description 1
238000009013 Lowry's assay Methods 0.000 description 1
101001130142 Mus musculus Low-density lipoprotein receptor Proteins 0.000 description 1
101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
241000710778 Pestivirus Species 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
208000004732 Systemic Vasculitis Diseases 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
108010033576 Transferrin Receptors Proteins 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
206010058874 Viraemia Diseases 0.000 description 1
206010051511 Viral diarrhoea Diseases 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000013459 approach Methods 0.000 description 1
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
229910052793 cadmium Inorganic materials 0.000 description 1
BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
230000006957 competitive inhibition Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
238000012258 culturing Methods 0.000 description 1
238000011461 current therapy Methods 0.000 description 1
230000001461 cytolytic effect Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
229940009976 deoxycholate Drugs 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
230000004927 fusion Effects 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
238000002955 isolation Methods 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
230000000897 modulatory effect Effects 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
238000012809 post-inoculation Methods 0.000 description 1
229940124606 potential therapeutic agent Drugs 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
229960000329 ribavirin Drugs 0.000 description 1
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
210000001944 turbinate Anatomy 0.000 description 1
230000007306 turnover Effects 0.000 description 1
239000011800 void material Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
229910000368 zinc sulfate Inorganic materials 0.000 description 1
239000011686 zinc sulphate Substances 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Physics & Mathematics (AREA)
Cell Biology (AREA)
Analytical Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Virology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pathology (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Zoology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Epidemiology (AREA)
Wood Science & Technology (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Endocrinology (AREA)

AU2002243382A 2000-10-25 2001-10-24 Method of inhibiting infection by HCV, other flaviviridae viruses, and any other virus that complexes to low density lipoprotein or to very low density lipoprotein in blood preventing viral entry into a cell Abandoned AU2002243382A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US24359400P	2000-10-25	2000-10-25
US60/243,594		2000-10-25
PCT/US2001/050701 WO2002048388A2 (fr)	2000-10-25	2001-10-24	Procede d'inhibition de l'infection au virus de l'hepatite c (vhc) et autres virus de la famille des flaviridae, et a tout autre virus formant dans le sang un complexe avec une lipoproteine de basse densite ou tres basse densite, par empechement de l'entree virale dans une cellule

Publications (1)

Publication Number	Publication Date
AU2002243382A1 true AU2002243382A1 (en)	2002-06-24

Family

ID=22919368

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2002243382A Abandoned AU2002243382A1 (en)	2000-10-25	2001-10-24	Method of inhibiting infection by HCV, other flaviviridae viruses, and any other virus that complexes to low density lipoprotein or to very low density lipoprotein in blood preventing viral entry into a cell

Country Status (6)

Country	Link
US (3)	US20050048062A1 (fr)
EP (1)	EP1592445A4 (fr)
JP (1)	JP2004529080A (fr)
AU (1)	AU2002243382A1 (fr)
CA (1)	CA2425513A1 (fr)
WO (1)	WO2002048388A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030105003A1 (en)	2001-04-05	2003-06-05	Jan Nilsson	Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
SE0103754L (sv) *	2001-04-05	2002-10-06	Forskarpatent I Syd Ab	Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
MXPA04002848A (es)	2001-09-28	2005-06-06	Esperion Therapeutics Inc	Prevencion y tratamiento de restenosis por administracion local de medicamento.
EP1732383A4 (fr)	2004-04-06	2007-05-02	Cedars Sinai Medical Center	Prevention et traitement des maladies vasculaires avec des vecteurs de virus associes aux adenovirus de recombinaison codant l'apolipoproteine a-i et l'apolipoproteine a-i milano
WO2006004660A2 (fr) *	2004-06-28	2006-01-12	Illumigen Biosciences, Inc.	Detection de mutations dans un gene associe a la resistance aux infections virales
FR2889532B1 (fr) *	2005-08-03	2007-10-12	Lab Francais Du Fractionnement	Anticorps diriges contre le recepteur du ldl
FR2889533B1 (fr) *	2005-08-03	2007-10-12	Lab Francais Du Fractionnement	Anticorps diriges contre le recepteur du ldl
US20080182895A1 (en) *	2006-08-25	2008-07-31	Howe Anita Y M	Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto
IL188628A0 (en) *	2008-01-07	2008-12-29	Yeda Res & Dev	Use of soluble ldl-r for viral hepatitis
BR112012029881A2 (pt)	2010-05-25	2019-09-24	Inserm (Institut National De La Santé De La Recherche Médicale)	combinação de anticorpos anti-envelope e anticorpos anti-receptor para o tratamento e a presenção de infecção por hcv
US9205139B2 (en)	2010-11-12	2015-12-08	Cardiovax, Llc	Immunomodulatory methods and systems for treatment and/or prevention of aneurysms
EP2637689A2 (fr)	2010-11-12	2013-09-18	Cedars-Sinai Medical Center	Procédés et systèmes immunomodulateurs pour le traitement et/ou la prévention de l'hypertension
US9234026B2 (en)	2011-07-21	2016-01-12	University of Pittsburgh—of the Commonwealth System of Higher Education	Apolipoprotein E polypeptides and their use
WO2013024157A2 (fr)	2011-08-17	2013-02-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Combinaisons d'agents ciblant un hôte pour le traitement et la prévention d'une infection par le vhc
WO2013024156A2 (fr)	2011-08-17	2013-02-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Combinaisons d'anticorps contre le facteur d'entrée du vhc et d'interférons pour le traitement et la prévention d'une infection par le vhc
WO2013024155A1 (fr)	2011-08-17	2013-02-21	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Combinaisons d'anticorps anti-facteur d'entrée de vhc et d'agents antiviraux à action directe pour le traitement et la prévention de l'infection par le vhc
WO2024249354A1 (fr) *	2023-05-26	2024-12-05	Vertex Pharmaceuticals Incorporated	Procédés pour diriger des nanoparticules lipidiques in vivo
WO2025081338A1 (fr) *	2023-10-17	2025-04-24	Wuhan Institute Of Virology, Chinese Academy Of Sciences	Modulation du récepteur des lipoprotéines de faible densité pour le traitement d'infections

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5496926A (en) *	1992-01-19	1996-03-05	Yeda Research And Development Co. Ltd.	Process of preparing a soluble LDL receptor
WO1999038524A2 (fr) *	1998-01-29	1999-08-05	Patrick Thomas Prendergast	Administration de ldl-r a des fins therapeutiques contre les infections virales et comme immunoregulateurs

2001
- 2001-10-24 JP JP2002550102A patent/JP2004529080A/ja active Pending
- 2001-10-24 WO PCT/US2001/050701 patent/WO2002048388A2/fr not_active Ceased
- 2001-10-24 EP EP01989275A patent/EP1592445A4/fr not_active Withdrawn
- 2001-10-24 US US10/398,200 patent/US20050048062A1/en not_active Abandoned
- 2001-10-24 AU AU2002243382A patent/AU2002243382A1/en not_active Abandoned
- 2001-10-24 CA CA002425513A patent/CA2425513A1/fr not_active Abandoned
2007
- 2007-06-20 US US11/820,987 patent/US20080213287A1/en not_active Abandoned
2009
- 2009-02-26 US US12/380,346 patent/US20110229482A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP2004529080A (ja)	2004-09-24
EP1592445A2 (fr)	2005-11-09
EP1592445A4 (fr)	2007-01-10
US20110229482A1 (en)	2011-09-22
US20080213287A1 (en)	2008-09-04
US20050048062A1 (en)	2005-03-03
CA2425513A1 (fr)	2002-06-20
WO2002048388A9 (fr)	2003-01-23
WO2002048388A3 (fr)	2005-09-15
WO2002048388A2 (fr)	2002-06-20

Publication	Publication Date	Title
US20110229482A1 (en)	2011-09-22	Method of inhibiting infection by HCV, other flaviviridae viruses, and any other virus that complexes to low density lipoprotein or to very low density lipoprotein in blood by preventing viral entry into a cell
Agnello et al.	1999	Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor
Leung et al.	1989	Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease
Hajjar	1991	Warner-Lambert/Parke-Davis Award Lecture. Viral pathogenesis of atherosclerosis. Impact of molecular mimicry and viral genes
Agnello	1997	The etiology and pathophysiology of mixed cryoglobulinemia secondary to hepatitis C virus infection
JP3675819B2 (ja)	2005-07-27	Ｃｄ４０に対する抗体
US7816497B2 (en)	2010-10-19	Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
EP1097172A1 (fr)	2001-05-09	Anticorps contre le virus de l'hepatite c et ses utilisations
Dumann et al.	1990	Hepatitis B vaccination and interleukin 2 receptor expression in chronic renal failure
Barba et al.	1983	Lung injury mediated by antibodies to endothelium. I. In the rabbit a repeated interaction of heterologous anti-angiotensin-converting enzyme antibodies with alveolar endothelium results in resistance to immune injury through antigenic modulation.
Matsuo et al.	1994	Role of CD59 in experimental glomerulonephritis in rats
De Moura et al.	1975	Cell-Mediated Immune Reactivity to Hepatitis Β Surface Antigen in Liver Diseases
Magro et al.	2007	Cytomegalovirus-associated cutaneous vasculopathy and scleroderma sans inclusion body change
EP0260691A2 (fr)	1988-03-23	Immunothérapie pour les patients atteints du SIDA
CA2228765A1 (fr)	1997-02-27	Compositions pharmaceutiques servant a l'inhibition competitive de la fixation d'un retrovirus sur le recepteur ifn et procede de diagnostic d'une infection a vih
Nagafuchi et al.	1986	Expression of β2− microglobulin on hepatocytes in acute and chronic type B hepatitis
Mondelli et al.	1986	In-vitro cell-mediated cytotoxicity for autologous liver cells in chronic non-A, non-B hepatitis
Lamprecht et al.	1998	Mixed cryoglobulinemia, glomerulonephritis, and ANCA: essential cryoglobulinaemic vasculitis or ANCA-associated vasculitis?
Mazzaro et al.	1994	Long-term effects of alpha-interferon therapy for type II mixed cryoglobulinemia
AU684455B2 (en)	1997-12-18	Production of human monoclonal antibodies active against hepatitis B surface antigen
Lin et al.	1986	Studies of circulating immune complexes and lymphocyte subpopulations in childhood IgM mesangial nephropathy
Niemann et al.	1984	The use of monoclonal antibodies as probes of the three-dimensional structure of human complement factor D.
Wallaert et al.	1992	Bronchoalveolar lavage in alcoholic liver cirrhosis: T-lymphocyte subsets and immunoglobulin concentrations
Nishihara	1983	Intrahepatic distribution of T cell and T cell subsets in cases with type B chronic liver disease by peroxidase-labeled antibody method using monoclonal antibodies
JPH08510635A (ja)	1996-11-12	Ｂ型肝炎エスケープミュータント特異的結合分子